VEGF gene variability and type 1 diabetes: Evidence for a protective role

Immunogenetics

Volumn 58, Issue 2-3, 2006, Pages 107-112

  Del Bo, Roberto ^a,b   Scarlato, Marina ^a,b   Ghezzi, Serena ^a,b   Maestroni, Anna ^c   Sjölind, Lisa ^d,e   Forsblom, Carol ^d,e   Wessman, Maija ^d,e,f   Groop, Per Henrik ^d,e   Comi, Giacomo Pietro ^a,b   Bresolin, Nereo ^a,b   Luzi, Livio ^c   Zerbini, Gianpaolo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cytokines; Human; Tolerance; Type 1 diabetes

Indexed keywords

ANGIOGENIC FACTOR; VASCULOTROPIN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELL PROTECTION; CHRONIC DISEASE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVASCULARIZATION;

ADULT; AGE OF ONSET; AGED; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; FEMALE; FINLAND; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645456005     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-006-0089-2     Document Type: Article

References (20)

1. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639
2. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245-1249
3. Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio F, Galbiati S, Virgilio R, Galimberti D, Galimberti G, Crimi M, Ferrarese C, Scarpini E, Bresolin N, Comi GP (2005) VEGF gene variability is associated with increased risk of Alzheimer's disease. Ann Neurol 57:373-380
4. Gale EAM, Gillespie KM (2001) Diabetes and gender. Diabetologia 44:3-15
5. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, and Carmeliet P (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383-394
6. Lammert E, Cleaver O, Melton D (2001) Induction of pancreatic differentiation by signals from blood vessels. Science 294:564-567
7. Mandrup-Poulsen T (2003) Beta cell death and protection. Ann N Y Acad Sci 1005:32-42
8. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, Fagerudd JA, Groop PH (2004) FinnDiane Study Group. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 27:503-509
9. Pociot F, McDermott MF (2002) Genetics of type 1 diabetes mellitus. Genes Immun 3:235-249
10. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P (2004) Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53:861-864
11. Rich SS (1990) Mapping genes in diabetes: Genetic epidemiological perspective. Diabetes 39:1315-1319
12. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M (2000) Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23:1326-1332
13. Schranz DB, Lernmark A (1998) Immunology in diabetes: an update. Diabetes Metab Rev 14:3-29
14. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, Harden PN (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260-264
15. Stagner J, Mokshagundam S, Wyler K, Samols E, Rilo H, Stagner M, Parthasarathy L, Parthasarathy R (2004) Beta-cell sparing in transplanted islets by vascular endothelial growth factor. Transplant Proc 36:1178-1180
16. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816
17. Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26:943-954
18. Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493-1495
19. Winter WE, Schatz D (2003) Prevention strategies for type 1 diabetes: current status and future directions. BioDrugs 17:39-64
20. Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, Zhang H, Song K, Meseck M, Bromberg J, Dong H (2004) Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 53:963-970